tiprankstipranks
Trending News
More News >

ProKidney Announces Promising Phase 2 Trial Results

Story Highlights
  • ProKidney Corp. announced positive results from its Phase 2 REGEN-007 trial on July 8, 2025.
  • The trial showed significant improvement in kidney function with rilparencel, supporting ongoing Phase 3 studies.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
ProKidney Announces Promising Phase 2 Trial Results

Don’t Miss TipRanks’ Half-Year Sale

ProKidney ( (PROK) ) has shared an update.

On July 8, 2025, ProKidney Corp. announced statistically significant and clinically meaningful topline results from its Phase 2 REGEN-007 trial, which evaluated rilparencel in patients with CKD and diabetes. The study showed a robust improvement in kidney function for Group 1, with a 78% improvement in eGFR slope, and evidence of a dose response in Group 2. No serious adverse events related to rilparencel were observed. The results bolster confidence in the ongoing Phase 3 PROACT 1 study and support the use of eGFR slope as a surrogate endpoint for accelerated approval. ProKidney plans to submit the full results to the American Society of Nephrology 2025 Kidney Week.

The most recent analyst rating on (PROK) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on ProKidney stock, see the PROK Stock Forecast page.

Spark’s Take on PROK Stock

According to Spark, TipRanks’ AI Analyst, PROK is a Underperform.

ProKidney’s stock score is significantly impacted by its poor financial performance, characterized by weak revenue growth, high operational costs, and negative cash flow. The technical analysis suggests a bearish trend with mixed indicators, while the valuation reflects high volatility and risk due to negative earnings. Overall, the financial instability and operational challenges are the primary concerns, leading to a low stock score.

To see Spark’s full report on PROK stock, click here.

More about ProKidney

ProKidney Corp. is a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD). The company is developing rilparencel, an autologous cellular therapy, to preserve kidney function in patients with advanced CKD and type 2 diabetes. ProKidney’s market focus includes patients with Stage 3b/4 CKD and diabetes, a significant population in the U.S. with unmet clinical needs.

Average Trading Volume: 1,137,111

Technical Sentiment Signal: Sell

Current Market Cap: $177.5M

Learn more about PROK stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1